Creoptix
Develops next generation instruments for the high-sensitivity analysis of label-free molecular interactions.
| EUR | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1 % | (8 %) | 4 % | - | 24 % | - | 12 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Creoptix AG specializes in advanced biosensor technology designed for drug discovery and life sciences. Utilizing proprietary Grating Coupled Interferometry (GCI) technology, the Creoptix WAVE system offers unparalleled resolution in signal and time, enabling accurate measurement of kinetic rates, affinity constants, and biomolecular interactions even at low analyte concentrations. The company serves research laboratories in both academic and industrial settings, providing tools that streamline workflows and enhance data precision. Operating in the biosensor market, Creoptix generates revenue through the sale of its WAVE systems and accompanying software, WAVEcontrol. The business model focuses on delivering high-value, cutting-edge technology to researchers who require precise and reliable data for their experiments.
Keywords: biosensors, drug discovery, life sciences, GCI technology, kinetic data, affinity constants, biomolecular interactions, research labs, WAVE system, WAVEcontrol software.